STOCK TITAN

Diagnamed Holdings Corp - DGNMF STOCK NEWS

Welcome to our dedicated news page for Diagnamed Holdings (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on Diagnamed Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Diagnamed Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Diagnamed Holdings's position in the market.

Rhea-AI Summary
DiagnaMed Holdings Corp. expands its CERVAI™ Brain Health AI Platform by adding Drexel University as a test launch site. The platform estimates BRAIN AGE® and provides a brain health score, aiming to detect potential brain health issues and cognitive decline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
DiagnaMed Holdings Corp. receives approval for trademark registration of its BRAIN AGE® brand for commercial use in Canada, as part of its CERVAI™ Brain Health AI Platform. The company is expanding its commercial initiatives and collaborating with leading research hospitals in Canada. The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DiagnaMed Holdings Corp. announces potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs to strengthen its intellectual property portfolio for commercializing CERVAI™ Brain Health AI solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Rhea-AI Summary
DiagnaMed Holdings Corp. has been accepted into the HEALTHI program to accelerate clinical research and commercialization efforts in Canada for its CERVAI™ Brain Health AI Platform. The program aims to establish relationships with leading clinicians and hospital facilities to improve brain health assessment and intervention. CERVAI™ combines Brain Age™ Estimation and Brain Health Assessment tools to identify potential brain health issues, offering personalized diagnostics and interventions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
76.52%
Tags
AI
-
Rhea-AI Summary
DiagnaMed Holdings Corp. announces the test launch of CERVAI™, a consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health. The platform assesses brain health through a Resilience Index, Vulnerability Index, and Number-Symbol Coding Task, showing promising results in detecting Alzheimer's disease risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DiagnaMed Holdings Corp. announced the pilot launch of CERVAI™, a consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. The solution aims to help bridge gaps in physical and cognitive health, providing personalized interventions to improve overall brain health. CERVAI™ is based on research and development at Drexel University and the University of Miami, combining Brain Age™ Estimation and Brain Health Assessment tools. The pilot program is open to 25 consumer wellness clinics in the U.S. and Canada over the next three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Rhea-AI Summary
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) has been accepted into the SOPHIE Program to accelerate clinical and commercialization efforts in Canada for the CERVAI™ Brain Health AI Platform. The program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. CERVAI™ consists of a Brain Age™ Estimation and Brain Health Assessment tool, integrating proprietary software and machine-learning models. The launch of the initial commercial version is expected in December 2023, with first sales to occur throughout Q1-2024. Discussions for international commercialization are underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
DiagnaMed launches CERVAI™ Healthcare Provider Network to expand access to its brain health AI platform for healthcare providers. The program is open for enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
DiagnaMed provides update on CERVAI™ commercialization
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Diagnamed Holdings Corp

OTC:DGNMF

DGNMF Rankings

DGNMF Stock Data

3.25M
70.48M
11.95%
Health Information Services
Healthcare
Link
Canada
Toronto